Methods
cerebral tumor, alcoholic psychosis, epilepsy, psychiatric, schizophrenia, drug dependence
DISORDERS, CARDIAC DISEASE, EPILEPSY
We began by analyzing the baseline data of our previous clinical schizophrenia trial, the details of which are described in clinical protocol NCT03788759 (ClinicalTrials.gov), and results published in reference [The sample consisted of 35 patients (12 women and 23 men) between 18 and 60 and diagnosed with schizophrenia, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition [All patients had been on stable antipsychotic doses for at least one year prior to the study. All were in stable condition. Exclusion criteria were: history of epilepsy or cerebral tumor; current valproic acid use; severe gastric, hepatic, renal, or cardiac disease; alcoholic psychosis; drug dependence, pregnancy, or lactation; co-morbid psychiatric diagnoses. All patients provided free and informed consent according to established ethical guidelines. Participants were verbally informed of their rights, the research protocol and purpose were thoroughly explained, and they provided written consent. In some cases, where decisional capacity was in doubt, the patient and a legal guardian signed consent. The research ethics committee of the Walter Cantídio University Hospital (CEP/HUWC) approved the study protocol (92598718.1.0000.5054).We calculated the baseline antipsychotic dose in chlorpromazine equivalent units using a conversion table [After testing the relevant data sets for normality with the Shapiro-Wilk test, we checked for correlations using the Pearson correlation coefficient. For comparison between groups, we used the Welch 